From professional translators, enterprises, web pages and freely available translation repositories.
alternatives to clarithromycin, such as azithromycin should be considered.
overvejes, da clarithromycins aktive metabolit har en reduceret virkning over for mycobacterium avium- intracellulær kompleks.
macrolide antibiotics (e. g. azithromycin, clarithromycin, erythromycin). a
protopy eller til makrolide antibiotika (f. eks. azithromycin, clarithromycin, erythromycin).
no dosage adjustment is necessary when azithromycin is given in combination with efavirenz.
dosisjustering er ikke nødvendig, når azithromycin gives i kombination med efavirenz.
based on the biliary elimination pathway of azithromycin, no drug interactions are expected between azithromycin and intelence.
eftersom azithromycin udskilles via galdevejene, forventes ingen lægemiddelinteraktioner mellem azithromycin og intelence.
medicines to treat bacterial or fungal infections (e.g. nafcillin, azithromycin, roxithromycin, clotrimazole)
lægemidler til behandling af bakterie- og svampeinfektioner (f.eks. nafcillin, azithromycin, roxithromycin, clotrimazol)
azithromycin: co-administration of single doses of azithromycin and multiple doses of efavirenz in uninfected volunteers did not result in any clinically significant pharmacokinetic interaction.
azithromycin:samtidig administration af enkeltdoser af azithromycin og multiple doser af efavirenz til ikke-inficerede frivillige medførte ingen klinisk signifikant farmakokinetisk interaktion.
based on known metabolic profiles, clinically significant interactions are not expected between kaletra and fluvastatin, dapsone, trimethoprim/ sulfamethoxazole, azithromycin or fluconazole.
54 baseret på kendte metabolske profiler forventes ingen klinisk signifikante interaktioner mellem kaletra og fluvastatin, dapson, trimethoprim/ sulfamethoxazol, azithromycin eller fluconazol.
macrolide antibiotics:azithromycin: co-administration of single doses of azithromycin and multiple doses of efavirenz in uninfected volunteers did not result in any clinically significant pharmacokinetic interaction.
102 administration med efavirenz, og at rifabutindosis måske skal fordobles i regimer, hvor rifabutin gives to eller tre gange ugentligt i kombination med efavirenz.makrolidantibiotika:azithromycin:samtidig administration af enkeltdoser af azithromycin og multiple doser af efavirenz til ikke-inficerede frivillige medførte ingen klinisk signifikant farmakokinetisk interaktion.
erythromycin (cyp3a4 inhibitor; 1 g twice daily) and azithromycin (500 mg once daily) had no significant effect on voriconazole cmax and auc.
erythromycin (cyp3a4-hæmmer; 1g 2 gange dagligt) og azithromycin (500 mg én gang dagligt) har ingen signifikant effekt på voriconazols cmax og auc.
studies conducted with other medicinal products: there were no clinically significant pharmacokinetic interactions when efavirenz was administered with azithromycin, cetirizine, lorazepam, nelfinavir, zidovudine, aluminium/ magnesium hydroxide antacids, famotidine or fluconazole.
der var ingen klinisk signifikante farmakokinetiske interaktioner, når efavirenz blev administreret sammen med azithromycin, cetirizin, lorazepam, nelfinavir, zidovudin, aluminium/ magnesiumhydroxidantacida, famotidin eller fluconazol.